

INTELLECT/SEC/2021-22

May 12, 2021

- 1. The National Stock Exchange of India Ltd.,**
Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051.
- 2. The BSE Ltd.**
1st Floor, New Trade Ring, Rotunda Building, PJ Towers,
Dalal Street, Fort,
Mumbai – 400 001.

Scrip Code :
INTELLECT

Scrip Code :
538835

Dear Sir(s),

Sub-Copy of newspaper advertisement

Kindly find the enclosed a copy of newspaper advertisement on the audited financial results of the Company for the quarter and financial year ended March 31, 2021 being published in “The Hindu”-Tamil and “Business line”-English dated May 12, 2021 respectively.

Kindly take the same on record and confirm Compliance.

Thanking you,

Yours Truly,

For Intellect Design Arena Limited,



V V Naresh

Company Secretary and Compliance officer

Intellect Design Arena Limited

Registered Office: 244 Anna Salai, Chennai - 600 006, India | Ph: +91-44-6615 5100 | Fax: +91-44-6615 5123
Corporate Headquarters: SIPCOT IT Park Siruseri, Chennai - 600 130, India | Ph: +91-44-6700 8000 | Fax: +91-44-6700 8874
E-mail: contact@intellectdesign.com | www.intellectdesign.com

Experts against ‘irrational’ use of plasma

Say this could lead to the possibility of more virulent Covid strains developing

PRESS TRUST OF INDIA

New Delhi, May 11

Some clinicians and scientists have written to Principal Scientific Advisor K Vijay Raghavan, cautioning against the “irrational and non-scientific use” of convalescent plasma for Covid-19 in the country.

Not based on evidence

The public health professionals said the current evidence on plasma therapy and the Indian Council of Medical Research (ICMR) guidelines are not based on the existing evidence.

They also pointed out some very early evidence that indicates a possible association between emergence of variants with “lower susceptibility to neutralising antibodies in immuno-suppressed” people given plasma therapy. This

raises the possibility of more virulent strains developing due to irrational use of plasma therapy, which can fuel the pandemic, said the letter signed by experts such as vaccinologist Gagandeep Kang and surgeon Pramesh CS.

“We are writing to you as concerned clinicians, public health professionals and scientists from India about the irrational and non-scientific use of convalescent plasma for Covid-19 in the country,” it said.

“This has stemmed from guidelines issued by government agencies, and we request your urgent intervention to address the issue, which can prevent harassment of Covid-19 patients, their families, their clinicians and Covid-19 survivors,” said the letter, which was also marked to Director



General of the Indian Medical Council of India, Balram Bhargava, and AIIMS Director, Randeep Guleria.

The concerns were raised after the Union Health Ministry last month issued an updated revised ‘Clinical Guidance for Management of Adult Covid-19 Patients’, under which it recommended off-label use of convalescent plasma only in the early moderate disease, preferably within seven days of onset of symptoms.

It also stated that “no use after seven days” and only on availability of high titre

donor plasma. “The current research evidence unanimously indicates that there is no benefit offered by convalescent plasma for treatment of Covid-19. However, it continues to be prescribed rampantly in hospitals across India,” said the letter.

Families of patients run from pillar-to-post to get plasma, which is in short supply.

The desperation of patients and their families is understandable because they like to try the best for their loved ones when a doctor has prescribed this, said the public health professionals.

What is plasma therapy?

In plasma therapy, antibodies from the blood of a patient who has recovered from Covid-19 are used to treat serious patients.

They said the current evidence on plasma therapy in Covid-19 and the ICMR guidelines are not based on

the existing evidence.

They cited the ICMR-PLA-CID trial, which was the world’s first randomised controlled trial on convalescent plasma in 39 public and private hospitals across India.

It found “convalescent plasma was not associated with a reduction in progression to severe Covid-19 or all-cause mortality. This trial has high generalisability and approximates convalescent plasma use in real life settings with limited laboratory capacity”.

The large trial of 11,588 patients found no difference in death or proportion of patients discharged from hospital, the clinicians said. Even for those patients who were not on ventilation initially, there was no difference

“in the proportion meeting the composite endpoint of progression to invasive mechanical ventilation or death”, they pointed out.

‘Maharashtra lockdown likely to be extended beyond May 15’

Decision to be taken at Cabinet meet today, says Health Minister

OUR BUREAU

Mumbai, May 11

The Maharashtra government, which has imposed a lockdown in the State to prevent the spread of Covid, is expected to extend it for a few more days after May 15. A decision on this issue is expected to be taken at the Cabinet meeting on Wednesday, said Rajesh Tope, Health Minister.

Tope, while interacting with mediapersons on Tuesday, said that only the Cabinet can decide on the lockdown. The conditions laid out in the lockdown will not be immediately relaxed.

In the State, 1.84 crore vaccinations have been carried out. The State government is required to be given a second dosage to persons above 45 years of age.



Rajesh Tope, Health Minister

Therefore, 3 lakh doses purchased by the State government, could be given to this age group, he said.

In one of his earlier press conferences, Tope had indicated that if the Centre does not provide vaccines for the age group above 45 years, then it will be forced to use the stock meant for the age group between 18 and 44.

Free vaccination

He said that the State government had announced free vac-

cinations for those in the 18 to 44 age group. But vaccine stocks are scarce. For those above the 45 age group, who have not been given the second dose, the first dose may become ineffective. Therefore, the stock of vaccine for the 18 to 44 age group, may have to be diverted to the 45 years-plus age group.

Chief Minister Uddhav Thackeray has been updated about this situation. The State Task Force will be consulted, and the decision of diverting the stock will be taken in the Cabinet meeting. Therefore, the pace of vaccination for the 18 to 44 year age group will be slow for a few days, he said.

Some Covid patients have also been infected with mucormycosis (rare fungal infection). Treatment for such patients will be provided free of cost at the government hospital under Mahatma Phule Janaarogya Yojana. The State government will bear the cost of the medicine, said the Minister.

Kejriwal wants Centre to enable more firms to produce vaccines

Delhi CM calls for a national plan to vaccinate all

OUR BUREAU

New Delhi, May 11

To meet the high demand for Covid vaccines in the country, the Centre should enable more companies to manufacture vaccines for the benefit of the people.

Addressing a virtual press conference, Delhi Chief Minister Arvind Kejriwal said the know-how on the manufac-

ture of Covid vaccines – currently available only with Serum Institute of India and Bharat Biotech – could be shared with other firms and appropriate royalty be paid to these two firms.

“Only two companies now produce vaccines. They produce only 6 to 7 crore vaccines a month. This way it will take over two years to vaccinate everyone in the country. Many Covid-19 waves would have come by then. It is important to increase vaccine production on

war footing and frame a national plan to vaccinate all. Not just two, several companies should be deployed to produce vaccines. The Centre should collect the formula to produce vaccines from these two existing companies, and give it to all those companies that can produce vaccine safely. Centre has the power to do this in these difficult times.”

Writes to PM

On Tuesday, Kejriwal wrote to the Prime Minister Narendra

Modi seeking his intervention in the matter of handing over the vaccine formula to more companies.

Downward slide

Kejriwal highlighted at the press conference that the number of new Covid infections is coming down in the national capital. He also said that the ongoing lockdown has been successful and the city has also been able to improve its health infrastructure.

Meanwhile, in the last 24

hours to Tuesday, Delhi’s new Covid-19 infections declined to 12,481, the lowest daily tally since April 12. On Monday, new Covid-19 infections stood at 12,651. The daily test positivity rate slid down further to 17.76 per cent, the lowest since April 16.

However, the number of daily deaths went up to 347 on Tuesday, the latest Delhi State Health Bulletin showed. This was higher than the 319 deaths as of Monday and 273 recorded on Sunday.

Bombay HC allows Bharat Biotech’s unit to make Covaxin at Pune facility

OUR BUREAU

Mumbai, May 11

The Bombay High Court has permitted a unit of Bharat Biotech to start manufacturing Covaxin at a ready-to-use vaccine manufacturing plant in Pune.

Biovet Private Limited had filed a plea with the court after the Forest Department objected the use of the

manufacturing unit at Manjari Khurd village in Pune. The unit was being used by Intervet India Pvt Ltd to manufacture vaccine for Foot and Mouth Disease. Intervet, owned by German major Merck, had agreed to transfer the land and the manufacturing facility to Biovet. However, the Pune division of the forest conserva-

tion department, objected to the use of the plant, arguing that the earlier permission given in 1973 itself was bad.

The court, however, ruled that given the current situation, Biovet should be allowed to run the plant.

Maharashtra government did not raise any objections to the court ruling, but said that but the company should not claim any right, title and interest in the future.

FDA clears Pfizer’s Covid vaccine for children in the 12-15 age group

Moderna is also undertaking vaccine trials on a similar age group

OUR BUREAU

Mumbai, May 11

Adolescents in the 12 to 15 age group in the US are now eligible to take the Pfizer-BioNTech Covid-19 vaccine after it received the regulatory go-ahead.

The US Food and Drug Administration (FDA) said it had expanded the emergency-use authorisation (EUA) on the Pfizer-BioNTech Covid-19 to include adolescents 12 through 15 years of age.

This involved amending the EUA originally issued early December for administration in individuals 16 years of age and older.

The mRNA vaccine is administered as a series of two doses, three weeks apart, the same dosage and dosing regimen for 16 years of age and older, the regulator said. The other mRNA vac-



disease course as compared to adults, the regulator said.

The FDA has determined that the Pfizer-BioNTech Covid-19 vaccine met the criteria to amend the EUA, and the known and potential benefits of this vaccine in the target age-group outweighed the known and potential risks, supporting the vaccine’s use in this population, it said.

“Having a vaccine authorized for a younger population is a critical step in continuing to lessen the immense public health burden caused by the pandemic,” said Peter Marks, Director of the FDA’s Center for Biologics Evaluation and Research.

Safety data

The FDA said that their safety data on the said age-group included 2,260 participants aged 12 through 15 years, enrolled in an ongoing randomised, placebo-controlled clinical trial in the US.

Of these, 1,131 adolescent participants received the vaccine and 1,129 received a saline placebo.

cine, from American biotech company Moderna, is also undertaking vaccine trials on a similar age group. In fact, both companies are also looking at the sub-12 age group, up to six months.

Janet Woodcock, acting FDA Commissioner, said the emergency approval to protect a younger population against Covid-19 brought them “closer to returning to a sense of normalcy and to ending the pandemic”.

From March 1, 2020, through April 30, 2021, approximately 1.5 million Covid-19 cases in individuals 11 to 17 years of age have been reported to the Centers for Disease Control and Prevention (CDC). Children and adolescents generally have a milder Covid-19

Resident associations, builders pitch in to nurse Covid patients

MEENAKSHI VERMA AMBWANI/
MONIKA YADAV

New Delhi, May 11

With the healthcare system coming under pressure as the country battles the second wave, Resident Welfare Associations (RWAs) and some builders are pitching in by setting up Covid care centres in collaboration with health professionals. In fact, some malls have also collaborated with local authorities for vaccination drives.

Such facilities are being equipped with oxygen cylinders and concentrators to help Covid patients with mild symptoms.

Real estate developer M3M Group has collaborated with Indian Air Force to set up a 150-bed Covid Care Centre at Gurugram to provide food and medical facilities, including oxygen, at one of its apartment complexes.

Guidelines issued

Local authorities in cities such as Noida, Gurugram and New Delhi have also come out with guidelines for RWAs and Apartment Owner Associations (AOAs) to set up isolation centres or care facilities equipped with concentrators and oxygen cylinders for

patients with mild symptoms. JB Gupta, Secretary of RWA of Sahara Grace Condominium, in Gurugram, said the 5-bed Covid-care facility in the community centre at the complex, has given a lot of confidence to residents as they have some access to medical care during these challenging times.

“Noble residents such as Vishal Singh, who donated funds and others like Dr Nagraj, who guided the RWA, came together to set up this facility. Residents pooled in with concentrators and donated small oxygen cylinders. We also put to use the oxygen cylinder used for the swimming pool, bought bedding, medical supplies and the facility is manned by nursing staff and monitored by resident doctors,” he said.

AOAs and RWAs are also helping with oxygen cylinder refilling for patients under home care and ensuring that essential items get delivered to senior citizens and those in quarantine.

“We have arranged for two oxygen cylinders of 50 kg each and their refill, along with four oxygen generators of 28 litres each. We get oxygen delivered in

the golf carts to those who require. Over and above, we have also created a space for ambulances to park within the premises. We have a dedicated team for sanitisation and Covid garbage collection,” Amit Modi, Director, ABA Corp, which owns Cleo County, a residential complex in Noida.

Vaccinations

Meanwhile, some malls in Mumbai have collaborated with local authorities to offer their premises for vaccinations.

Rajneesh Mahajan, CEO, Inorbit Malls, said: “We successfully conducted the first ‘drive through’ initiative by Navi Mumbai Municipal Corporation at our parking lot in a safe and hygienic manner. We see possibilities of ramping up the number of people that can be inoculated and would work closely with local authorities in executing such exercise.”

Sachin Dhanawade, COO, Retail and Real-Estate, Grauer & Weil India Ltd, said that the ‘drive-in’ vaccination centre at Grownl’s 101 mall will facilitate 250 senior citizens to get inoculated on a daily basis.

intellect®
Design for Digital

INTELLECT DESIGN ARENA LIMITED

CIN : L72900TN2011PLC080183

Regd Office : Carex Centre, 244 (Old No. 713) Anna Salai, Chennai 600 006

Corporate office : Plot No.3/G-3,SIPCOT IT Park, Siruseri, Chennai-600 130 Telephone Nos.: 044-6700 8000, Fax : 044-6700 8874

Website : www.intellectdesign.com, Email id :shareholder.query@intellectdesign.com, company.secretary@intellectdesign.com

AUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS OF INTELLECT DESIGN ARENA LIMITED FOR THE QUARTER AND YEAR ENDED MARCH 31, 2021

(Rs. in Millions)

Particulars	CONSOLIDATED		
	QUARTER ENDED		YEAR ENDED
	MARCH 31, 2021 Refer Note a	MARCH 31,2020 Refer Note a	MARCH 31, 2021 Refer Note a
Total Income from Operations	3,975.69	3,580.25	14,974.59
Profit / (Loss) for the period / year before share of profit / (loss) of associates, joint venture, exceptional item and tax	818.69	361.26	2,816.08
Net Profit / (Loss) for the period / year before tax (after Exceptional and/or Extraordinary items)	901.54	423.49	2,900.87
Net Profit / (Loss) for the period / year after tax (after Exceptional and/or Extraordinary items) - attributable to the Owners of the company	806.10	409.91	2,627.68
Total Comprehensive Income for the period / year [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)] - attributable to the Owners of the company	831.54	188.01	3,141.18
Equity Share Capital	664.87	661.69	664.87
Earnings Per Share (of Rs. 5/- each)			
1. Basic	6.07	3.10	19.82
2. Diluted	5.92	3.07	19.55

Particulars	STANDALONE		
	QUARTER ENDED		PERIOD ENDED
	MARCH 31, 2021 Refer Note a	MARCH 31,2020 Refer Note a	MARCH 31, 2021 Refer Note a
Total Income from Operations	2,803.04	2,036.66	10,032.28
Net Profit / (Loss) for the period / year (before Tax, Exceptional and/or Extraordinary items)	593.29	304.43	2,225.79
Net Profit / (Loss) for the period / year before tax (after Exceptional and/or Extraordinary items)	593.29	304.43	2,225.79
Net Profit / (Loss) for the period / year after tax (after Exceptional and/or Extraordinary items) - attributable to the Owners of the company	557.30	189.18	2,072.53
Total Comprehensive Income for the period / year [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)] - attributable to the Owners of the company	609.27	(114.28)	2,589.44
Equity Share Capital	664.87	661.69	664.87
Earnings Per Share (of Rs.5/- each)			
1. Basic	4.20	1.43	15.63
2. Diluted	4.09	1.42	15.42

NOTES :

a) The standalone and consolidated financial results for the quarter and year ended March 31, 2021 were approved by the Board of Directors at its meeting held on May 10, 2021. These financial results are prepared in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and relevant amendment rules thereafter. The statutory auditors have conducted an audit of the above standalone and consolidated financial results. Further, the standalone and consolidated financial results for the quarter ended March 31, 2021 and March 31, 2020 are balancing figure between audited figures in respect of the full financial year and the unaudited published year to date figures upto the third quarter ended December 31 for respective years which are subject to limited review.

b) Based on the "Management Approach" as defined under Ind AS 108 Operating Segments, the Company's performance is evaluated and resources are allocated based on an analysis of various performance indicators by a single business segment i.e. 'Software Product License & related services'.

c) The outbreak of Coronavirus (COVID-19) pandemic globally initially caused a slowdown of economic activity in 2020. Many countries including India continue to be impacted in the second wave of the COVID 19 in 2021. In many countries, businesses are being forced to limit their operations due to lockdowns of varying nature. Measures taken to contain the spread of the virus, including vaccines, travel bans, quarantines, social distancing, and closures of non-essential services have triggered disruptions to businesses worldwide pertaining to future operations. The Company has considered the possible effects that may result from COVID 19 on its operations including on the carrying amount of trade receivables, revenue accrued not billed, goodwill on consolidation, intangible assets and intangible assets under development. In developing the assumption relating to the possible future uncertainties in the global conditions because of the pandemic, the Company as on date of approval of these financial statements has used various information, as available. The Company has performed sensitivity analysis on the assumptions used and based on current indicators of future economic conditions.

d) The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified. The Company will assess the impact of the Code when it comes into effect and will record any related impact in the period when the Code becomes effective.

e) Figures of the earlier period, wherever necessary, have been regrouped to conform with those of the current periods.

For Intellect Design Arena Limited
Sd/-
Arun Jain
Chairman & Managing Director

Place : Chennai
Date : May 10, 2021